Determinants of benzodiazepine use in a representative population of HIV-infected individuals: the role of HIV status disclosure (ANRS-EN12-VESPA study).
Identifieur interne : 001695 ( Main/Corpus ); précédent : 001694; suivant : 001696Determinants of benzodiazepine use in a representative population of HIV-infected individuals: the role of HIV status disclosure (ANRS-EN12-VESPA study).
Auteurs : Perrine Roux ; Lionel Fugon ; Laurent Michel ; France Lert ; Yolande Obadia ; Bruno Spire ; Maria Patrizia CarrieriSource :
- AIDS care [ 1360-0451 ] ; 2011.
English descriptors
- KwdEn :
- Adult (MeSH), Anxiety Disorders (complications), Anxiety Disorders (drug therapy), Anxiety Disorders (epidemiology), Benzodiazepines (therapeutic use), Cross-Sectional Studies (MeSH), Female (MeSH), France (epidemiology), HIV Infections (complications), HIV Infections (epidemiology), HIV Infections (psychology), Humans (MeSH), Logistic Models (MeSH), Male (MeSH), Middle Aged (MeSH), Qualitative Research (MeSH), Risk Factors (MeSH), Social Stigma (MeSH), Social Support (MeSH), Stress, Psychological (MeSH), Truth Disclosure (MeSH).
- MESH :
- chemical , therapeutic use : Benzodiazepines.
- geographic , epidemiology : France.
- complications : Anxiety Disorders, HIV Infections.
- drug therapy : Anxiety Disorders.
- epidemiology : Anxiety Disorders, HIV Infections.
- psychology : HIV Infections.
- Adult, Cross-Sectional Studies, Female, Humans, Logistic Models, Male, Middle Aged, Qualitative Research, Risk Factors, Social Stigma, Social Support, Stress, Psychological, Truth Disclosure.
Abstract
HIV infection may result in stressful situations such as disclosure to others and could be a mediator between seropositivity status and psychiatric illness, depression, or anxiety. Several results have shown that anxiolytic use (mainly benzodiazepines [BDZ]) is highly prevalent in HIV-infected individuals, but few studies have highlighted to what extent this use could be associated with HIV disclosure. A national cross-sectional survey representative of people living with HIV and AIDS in France enrolled 2932 individuals in 102 French HIV hospital departments. Face-to-face interviews and self-administered questions collected information about patients' experience with HIV and HIV care, including use of psychotropic drugs, social support, stigma, and disclosure of HIV status. We identified factors associated with regular BDZ use (i.e., more than once a week) using a weighted logistic regression model. Regular BDZ use and anxiety symptoms were reported by 16% and 29% of the patients, respectively. After multiple adjustment for known correlates of BDZ use and anxiety symptoms, individuals who had disclosed their HIV status to relatives or friends were found to be more likely (OR [95% CI] = 1.78 [1.02-3.09]) to regularly use BDZ. These results show both to what extent disclosure to others continues to be a stressful step in the course of HIV infection and that disclosure is something that could be identified by BDZ use. They also highlight the need for appropriate case management and psychiatric care to help patients manage the consequences of disclosure.
DOI: 10.1080/09540121.2011.555738
PubMed: 21562996
Links to Exploration step
pubmed:21562996Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Determinants of benzodiazepine use in a representative population of HIV-infected individuals: the role of HIV status disclosure (ANRS-EN12-VESPA study).</title><author><name sortKey="Roux, Perrine" sort="Roux, Perrine" uniqKey="Roux P" first="Perrine" last="Roux">Perrine Roux</name><affiliation><nlm:affiliation>INSERM, U, Marseille, France. perrine.roux@inserm.fr</nlm:affiliation></affiliation></author><author><name sortKey="Fugon, Lionel" sort="Fugon, Lionel" uniqKey="Fugon L" first="Lionel" last="Fugon">Lionel Fugon</name></author><author><name sortKey="Michel, Laurent" sort="Michel, Laurent" uniqKey="Michel L" first="Laurent" last="Michel">Laurent Michel</name></author><author><name sortKey="Lert, France" sort="Lert, France" uniqKey="Lert F" first="France" last="Lert">France Lert</name></author><author><name sortKey="Obadia, Yolande" sort="Obadia, Yolande" uniqKey="Obadia Y" first="Yolande" last="Obadia">Yolande Obadia</name></author><author><name sortKey="Spire, Bruno" sort="Spire, Bruno" uniqKey="Spire B" first="Bruno" last="Spire">Bruno Spire</name></author><author><name sortKey="Carrieri, Maria Patrizia" sort="Carrieri, Maria Patrizia" uniqKey="Carrieri M" first="Maria Patrizia" last="Carrieri">Maria Patrizia Carrieri</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21562996</idno><idno type="pmid">21562996</idno><idno type="doi">10.1080/09540121.2011.555738</idno><idno type="wicri:Area/Main/Corpus">001695</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001695</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Determinants of benzodiazepine use in a representative population of HIV-infected individuals: the role of HIV status disclosure (ANRS-EN12-VESPA study).</title><author><name sortKey="Roux, Perrine" sort="Roux, Perrine" uniqKey="Roux P" first="Perrine" last="Roux">Perrine Roux</name><affiliation><nlm:affiliation>INSERM, U, Marseille, France. perrine.roux@inserm.fr</nlm:affiliation></affiliation></author><author><name sortKey="Fugon, Lionel" sort="Fugon, Lionel" uniqKey="Fugon L" first="Lionel" last="Fugon">Lionel Fugon</name></author><author><name sortKey="Michel, Laurent" sort="Michel, Laurent" uniqKey="Michel L" first="Laurent" last="Michel">Laurent Michel</name></author><author><name sortKey="Lert, France" sort="Lert, France" uniqKey="Lert F" first="France" last="Lert">France Lert</name></author><author><name sortKey="Obadia, Yolande" sort="Obadia, Yolande" uniqKey="Obadia Y" first="Yolande" last="Obadia">Yolande Obadia</name></author><author><name sortKey="Spire, Bruno" sort="Spire, Bruno" uniqKey="Spire B" first="Bruno" last="Spire">Bruno Spire</name></author><author><name sortKey="Carrieri, Maria Patrizia" sort="Carrieri, Maria Patrizia" uniqKey="Carrieri M" first="Maria Patrizia" last="Carrieri">Maria Patrizia Carrieri</name></author></analytic><series><title level="j">AIDS care</title><idno type="eISSN">1360-0451</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Anxiety Disorders (complications)</term><term>Anxiety Disorders (drug therapy)</term><term>Anxiety Disorders (epidemiology)</term><term>Benzodiazepines (therapeutic use)</term><term>Cross-Sectional Studies (MeSH)</term><term>Female (MeSH)</term><term>France (epidemiology)</term><term>HIV Infections (complications)</term><term>HIV Infections (epidemiology)</term><term>HIV Infections (psychology)</term><term>Humans (MeSH)</term><term>Logistic Models (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Qualitative Research (MeSH)</term><term>Risk Factors (MeSH)</term><term>Social Stigma (MeSH)</term><term>Social Support (MeSH)</term><term>Stress, Psychological (MeSH)</term><term>Truth Disclosure (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Benzodiazepines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Anxiety Disorders</term><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Anxiety Disorders</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Anxiety Disorders</term><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Qualitative Research</term><term>Risk Factors</term><term>Social Stigma</term><term>Social Support</term><term>Stress, Psychological</term><term>Truth Disclosure</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">HIV infection may result in stressful situations such as disclosure to others and could be a mediator between seropositivity status and psychiatric illness, depression, or anxiety. Several results have shown that anxiolytic use (mainly benzodiazepines [BDZ]) is highly prevalent in HIV-infected individuals, but few studies have highlighted to what extent this use could be associated with HIV disclosure. A national cross-sectional survey representative of people living with HIV and AIDS in France enrolled 2932 individuals in 102 French HIV hospital departments. Face-to-face interviews and self-administered questions collected information about patients' experience with HIV and HIV care, including use of psychotropic drugs, social support, stigma, and disclosure of HIV status. We identified factors associated with regular BDZ use (i.e., more than once a week) using a weighted logistic regression model. Regular BDZ use and anxiety symptoms were reported by 16% and 29% of the patients, respectively. After multiple adjustment for known correlates of BDZ use and anxiety symptoms, individuals who had disclosed their HIV status to relatives or friends were found to be more likely (OR [95% CI] = 1.78 [1.02-3.09]) to regularly use BDZ. These results show both to what extent disclosure to others continues to be a stressful step in the course of HIV infection and that disclosure is something that could be identified by BDZ use. They also highlight the need for appropriate case management and psychiatric care to help patients manage the consequences of disclosure.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21562996</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2011</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1360-0451</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>9</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>AIDS care</Title><ISOAbbreviation>AIDS Care</ISOAbbreviation></Journal><ArticleTitle>Determinants of benzodiazepine use in a representative population of HIV-infected individuals: the role of HIV status disclosure (ANRS-EN12-VESPA study).</ArticleTitle><Pagination><MedlinePgn>1163-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/09540121.2011.555738</ELocationID><Abstract><AbstractText>HIV infection may result in stressful situations such as disclosure to others and could be a mediator between seropositivity status and psychiatric illness, depression, or anxiety. Several results have shown that anxiolytic use (mainly benzodiazepines [BDZ]) is highly prevalent in HIV-infected individuals, but few studies have highlighted to what extent this use could be associated with HIV disclosure. A national cross-sectional survey representative of people living with HIV and AIDS in France enrolled 2932 individuals in 102 French HIV hospital departments. Face-to-face interviews and self-administered questions collected information about patients' experience with HIV and HIV care, including use of psychotropic drugs, social support, stigma, and disclosure of HIV status. We identified factors associated with regular BDZ use (i.e., more than once a week) using a weighted logistic regression model. Regular BDZ use and anxiety symptoms were reported by 16% and 29% of the patients, respectively. After multiple adjustment for known correlates of BDZ use and anxiety symptoms, individuals who had disclosed their HIV status to relatives or friends were found to be more likely (OR [95% CI] = 1.78 [1.02-3.09]) to regularly use BDZ. These results show both to what extent disclosure to others continues to be a stressful step in the course of HIV infection and that disclosure is something that could be identified by BDZ use. They also highlight the need for appropriate case management and psychiatric care to help patients manage the consequences of disclosure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roux</LastName><ForeName>Perrine</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>INSERM, U, Marseille, France. perrine.roux@inserm.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fugon</LastName><ForeName>Lionel</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Michel</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lert</LastName><ForeName>France</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Obadia</LastName><ForeName>Yolande</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Spire</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Carrieri</LastName><ForeName>Maria Patrizia</ForeName><Initials>MP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS Care</MedlineTA><NlmUniqueID>8915313</NlmUniqueID><ISSNLinking>0954-0121</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057545" MajorTopicYN="N">Social Stigma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014342" MajorTopicYN="Y">Truth Disclosure</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21562996</ArticleId><ArticleId IdType="pii">937486036</ArticleId><ArticleId IdType="doi">10.1080/09540121.2011.555738</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001695 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001695 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:21562996
|texte= Determinants of benzodiazepine use in a representative population of HIV-infected individuals: the role of HIV status disclosure (ANRS-EN12-VESPA study).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:21562996" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |